Vir Biotechnology (VIR) Total Non-Current Liabilities (2018 - 2026)

Vir Biotechnology's Total Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $179.6 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities fell 25.25% year-over-year to $179.6 million; the TTM figure through Mar 2026 stood at $179.6 million (down 25.25% YoY), while the FY2025 annual figure was $216.0 million, down 3.75% from the prior year.
• Total Non-Current Liabilities came in at $179.6 million for Q1 2026 at Vir Biotechnology, down from $216.0 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $867.2 million in Q1 2022 to a low of $179.6 million in Q1 2026.
• A 5-year average of $377.6 million and a median of $240.3 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities surged 101.81% in 2022 and plunged 68.12% in 2024, its largest moves.
• Vir Biotechnology's Total Non-Current Liabilities stood at $699.2 million in 2022, then slumped by 55.23% to $313.0 million in 2023, then slipped by 28.32% to $224.4 million in 2024, then retreated by 3.75% to $216.0 million in 2025, then dropped by 16.84% to $179.6 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $179.6 million, $216.0 million, and $189.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison